3-氯-2-甲酰基-4-甲基吡啶 | 884495-43-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氯-2-甲酰基-4-甲基吡啶
• 英文名称: 3-chloro-4-methylpicolinaldehyde
• 英文别名: 3-chloro-4-methylpyridine-2-carbaldehyde
• CAS: 884495-43-6
• 化学式: C₇H₆ClNO
• mdl: MFCD08277284
• 分子量: 155.584
• InChiKey: WRNWASKGNIVGFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-氯-2-甲酰基-4-甲基吡啶 在 二乙胺基三氟化硫 作用下， 以 二氯甲烷 为溶剂， 生成 3-chloro-2-(difluoromethyl)-4-methylpyridine
  参考文献：
  名称：

  [EN] TRICYCLIC GPR65 MODULATORS
  [FR] MODULATEURS TRICYCLIQUES DE LA GPR65

  摘要：

  One aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, (I) wherein: ring B is: a monocyclic aromatic group; or a monocyclic or bicyclic heteroaromatic group, each of which is optionally substituted by halo, CN, OH, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, hydroxycycloalkyl, O-cycloalkyl, alkoxy, haloalkoxy, heterocycloalkyl, O- heterocycloalkyl, aryl, heteroaryl, O-aryl, NHCO-alkenyl, NHCO-aryl, -(CH2)q-O-heteroaryl, CONH-aryl, aryloxy-alkyl, O-aralkyl, and CO2-alkyl, wherein said aryl, heteroaryl, heterocycloalkyl, O-cycloalkyl, NHCO-aryl, -(CH2)q-O-heteroaryl, CONH-aryl, aryloxy-alkyl, O-aralkyl, and O-aryl groups are each optionally further substituted by one or more groups independently selected from halo, alkyl, haloalkyl, alkoxy, NHCO-alkyl, NR13R13', SO2-alkyl, CN, hydroxyalkyl, CONR14R14', alkyl-NR15R15', heterocycloalkyl, alkyl-heterocycloalkyl, alkyl- cycloalkyl, aryl, (CH2)m-NHSO2-alkyl, CO2R16, alkoxy-alkyl, haloalkoxy, O-heterocycloalkyl, heteroaryl, alkoxy-alkoxy, and O-(CH2)p-cycloalkyl, where in the latter group, said cycloalkyl group is optionally further substituted by one or more halo, haloalkyl, alkyl or alkoxy groups; m is an integer from 0 to 3; p and q are each independently 0 to 3; Z is CR12; Y is CR10R10', wherein R10and R10'are each independently selected from H, F, alkyl, and haloalkyl; Raand Rbare each independently selected from H and alkyl; R6is selected from H, alkyl, cycloalkyl and hydroxyalkyl; R12is selected from H, alkyl, haloalkyl, halo, OH and O-alkyl; and R13, R13', R14, R14', R15, R15', and R16are each independently selected from H, alkyl, and alkoxyalkyl. Further aspects of the invention relate to compounds of formula (I) for use as a medicament, particularly in the field of immuno-oncology, immunology, and related applications.

  公开号：

  WO2023067322A1
• 作为产物：
  描述：

  3-chloro-4-methyl-2-vinylpyridine 在 臭氧 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 3-氯-2-甲酰基-4-甲基吡啶
  参考文献：
  名称：

  [EN] TRICYCLIC GPR65 MODULATORS
  [FR] MODULATEURS TRICYCLIQUES DE LA GPR65

  摘要：

  One aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, (I) wherein: ring B is: a monocyclic aromatic group; or a monocyclic or bicyclic heteroaromatic group, each of which is optionally substituted by halo, CN, OH, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, hydroxycycloalkyl, O-cycloalkyl, alkoxy, haloalkoxy, heterocycloalkyl, O- heterocycloalkyl, aryl, heteroaryl, O-aryl, NHCO-alkenyl, NHCO-aryl, -(CH2)q-O-heteroaryl, CONH-aryl, aryloxy-alkyl, O-aralkyl, and CO2-alkyl, wherein said aryl, heteroaryl, heterocycloalkyl, O-cycloalkyl, NHCO-aryl, -(CH2)q-O-heteroaryl, CONH-aryl, aryloxy-alkyl, O-aralkyl, and O-aryl groups are each optionally further substituted by one or more groups independently selected from halo, alkyl, haloalkyl, alkoxy, NHCO-alkyl, NR13R13', SO2-alkyl, CN, hydroxyalkyl, CONR14R14', alkyl-NR15R15', heterocycloalkyl, alkyl-heterocycloalkyl, alkyl- cycloalkyl, aryl, (CH2)m-NHSO2-alkyl, CO2R16, alkoxy-alkyl, haloalkoxy, O-heterocycloalkyl, heteroaryl, alkoxy-alkoxy, and O-(CH2)p-cycloalkyl, where in the latter group, said cycloalkyl group is optionally further substituted by one or more halo, haloalkyl, alkyl or alkoxy groups; m is an integer from 0 to 3; p and q are each independently 0 to 3; Z is CR12; Y is CR10R10', wherein R10and R10'are each independently selected from H, F, alkyl, and haloalkyl; Raand Rbare each independently selected from H and alkyl; R6is selected from H, alkyl, cycloalkyl and hydroxyalkyl; R12is selected from H, alkyl, haloalkyl, halo, OH and O-alkyl; and R13, R13', R14, R14', R15, R15', and R16are each independently selected from H, alkyl, and alkoxyalkyl. Further aspects of the invention relate to compounds of formula (I) for use as a medicament, particularly in the field of immuno-oncology, immunology, and related applications.

  公开号：

  WO2023067322A1

文献信息

• [EN] THERAPEUTIC HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES THÉRAPEUTIQUES
  申请人：GILEAD SCIENCES INC

  公开号：WO2019040102A1

  公开（公告）日：2019-02-28

  Compounds having the following Formula (I) and/or Formula (II) and methods of their use and preparation are disclosed.

  揭示了具有以下化学式（I）和/或化学式（II）的化合物，以及它们的使用和制备方法。
• Therapeutic heterocyclic compounds
  申请人：Gilead Sciences, Inc.

  公开号：US11040033B2

  公开（公告）日：2021-06-22

  Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:

  本发明公开了具有以下式 I 和/或式 II 的化合物及其使用和制备方法：
• THERAPEUTIC HETEROCYCLIC COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：EP3672970A1

  公开（公告）日：2020-07-01